|
Shareprice information |
|
Subscription service |
Financial reports
Latest interim report
28/10/2021 BioInvent Interim Report, January 1 - September 30, 2021
Download PDF (6MB)
Annual Report 2020
Download PDF (4.2MB)
Press releases:
Presentations
| Webcast | Link |
| CEO Martin Welschof presents at the Redeye Life Science Day, 11 November, 2021 | Click here |
| BioInvent Q3 2021 report audiocast, 28 October, 2021 | Click here |
| Interview with the CEO Martin Welschof, Redeye, 2 September, 2021 | Click here |
| Interview with the CEO Martin Welschof, Pareto Securities, September 1, 2021 | Click here |
| Presentation, Redeye Investor Forum Online, 11 May 2021 | Click here |
| BioInvent KOL Call: BI-1206 for Relapsed or Refractory NHL, 28 January, 2021 | Click here |
| Presentation, Fight Cancer Seminar Redeye, January 21, 2021 | Click here |
| Presentation, SEB Annual Healthcare Seminar 2021, January 18, 2021 | Click here |
| Presentation, DNB Nordic Healthcare Conference, December 15, 2020 | Click here |
| Di tv - Interview with Martin Welschof, CEO, October 27, 2020 | Click here |
| Pareto-TV - Interview with Martin Welschof, CEO, October 27, 2020 | Click here |
| Interview with the CEO, Erik Penser Bank, Cancer research – Frontline, October 7, 2020 | Click here |
| Presentation, Erik Penser Bank, Cancer research – Frontline, October 7, 2020 | Click here |
| Interview with Dharminder Chahal, Board member of BioInvent, September 23, 2020 | Click here |
| Interview with the CEO, Redeye, September 1, 2020 | Click here |
| Presentation of BioInvent's second quarter report 2020, Sweden, August 27, 2020 | Click here |
| Key Opinion Leader call with Prof. Alexander Eggermont, July 21, 2020 | Click here |
| Interview with Vincent Ossipow, Partner at Omega Fund, June 25, 2020 |
Click here |
| Interview with the CEO, Redeye, April 15, 2020 |
Click here |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, March 10, 2020 |
Click here |
| Presentation of BioInvent's fourth quarter report 2019, Sweden, February 27, 2020 | Click here |
| Interview with Martin Welschof, CEO, Redeye, Lund, Sweden, December 18, 2019 | Click here |
| Title | Download |
| Bioinvent Q3 2021 Report Slide Deck, October 28, 2021 | Download pdf (0.89 Mb) |
| Pareto Healtchare Conference, September 1, 2021 | Download pdf (1.04 Mb) |
| Drug Target Review Article By CSO Björn Frendéus, June 14, 2021 | Download pdf (0.88 Mb) |
| Interview With Björn Frendéus, CSO at Bioinvent, Pharmafile Spring 2021 p26 27 © Samedan Ltd, May 18, 2021 | Download pdf (0.19 Mb) |
| Bioinvent KOL Call, BI 1206 For Relapsed Or Refractory NHL, January 28, 2021 | Download pdf (2.51 Mb) |
| Presentation, DNB Nordic Healthcare Conference, December 15, 2020 | Download pdf (1.38 Mb) |
| Interview With The CEO, Pharmafocus, October, 2020 | Download pdf (0.46 Mb) |
| Audiocast with teleconference Q2 2020, Sweden, August 27, 2020 | Download pdf (0.57 Mb) |
| Key Opinion Leader Call With Prof. Alexander Eggermont, July 21, 2020 | Download pdf (2.61 Mb) |
| Poster Presentation AACR 2020, BT 001, June 22 24, 2020 | Download pdf (0.82 Mb) |
| Poster Presentation AACR 2020, Targeting TNFR2, June 22 24, 2020 | Download pdf (2.23 Mb) |
| Company Presentation, May, 2020 | Download pdf (1.7 Mb) |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, March 10, 2020 | Download pdf (0.52 Mb) |
| Bioinvent Audiocast With Teleconference Q4, Sweden, February 27, 2020 | Download pdf (0.87 Mb) |
| Company Presentation At JP Morgan, San Francisco, USA, January 13 16, 2020 | Download pdf (1.71 Mb) |
Investor information
Please find information in this section on our financial calendar, analysts who follow BioInvent and out largest owners.
Choose from the links to access the information.
Financial calendar
Analysts
Ownership
Corporate governance
BioInvent applies the Swedish Code of Corporate Governance ("the Code"). In addition to the Code, BioInvent also complies with applicable rules in the Swedish Companies Act, rules and recommendations ensuring from the Company's listing on NASDAQ OMX Stockholm, and good practices on the stock market.
Investor contact
Cecilia Hofvander
Senior Director Investor Relations
Tel. +46 (0)46-286 85 50
E-mail: cecilia.hofvander@bioinvent.com
Subscription service